Search results
Author(s):
John Petrie
Added:
4 years ago
Prof John Petrie (University of Glasgow, Glasgow, UK) discuss Metformin safety and efficacy in ASCVD.
Questions :
1. Can you give us a brief introduction to the role of metformin in ASCVD reduction?
2. What is the REMOVAL study and what did it measure?
3. Can you tell us the latest data from the REMOVAL subgroup studies?
4. Can you tell us the rationale behind the VA-IMPACT trial?
5. In the…
View more
Author(s):
Dato’ Dr Muhamad Ali
,
Oliver Weingärtner
Added:
2 years ago
Join us for this live broadcast where faculty will ensure physicians based in Malaysia are aware of the importance of risk stratification in relation to secondary prevention and how this is dealt with in the recent ESC guidance and why it's important. The faculty will make a distinct comparison between the ESC guidelines and what the Malaysian guidelines say is central to this, including why is…
View more
Author(s):
Michelle O'Donoghue
Added:
1 year ago
In this video, Dr Michelle L O’Donoghue summarises the long-term evaluation of evolocumab in the open label extension trial, FOURIER-OLE. The rationale of the study, the key results and how these add to the existing evidence will be discussed. This video will also highlight which patients would benefit the most from evolocumab, the safety profile in this extension study and take home-messages.
…
View more
CVD and Type 2 Diabetes
Video Series
Remnant Lipoproteins and ASCVD
Author(s):
Mohanad Gabani
,
Michael D Shapiro
,
Peter P Toth
Added:
6 months ago
Article
Author(s):
Anandita Agarwala
,
Michael D Shapiro
Added:
3 years ago
Atherogenic dyslipidaemia encompasses a broad variety of lipid phenotypes. While LDL cholesterol is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD), there are additional atherogenic lipoproteins that may be targeted to further reduce ASCVD risk.
In their comprehensive review, Lorenzatti and Toth emphasise that, even when LDL cholesterol levels are optimised, ASCVD…
View more
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
Added:
3 years ago
Source:
Esperion
News
Author(s):
Alberto Lorenzatti
,
Peter P Toth
Added:
3 years ago
We are witnessing an epidemic global increase in the prevalence of obesity and its clinical consequences (e.g. insulin resistance and diabetes). This epidemic has been potentiated and sustained by the widespread adoption of unhealthy lifestyles in broad swathes of the population and is characterised by a sedentary lifestyle and an imbalance between the type and characteristics of nutrition,…
View more
Author(s):
R Scott Wright
Added:
4 years ago
Prof R Scott Wright (Mayo Clinic, Rochester, MN, US) discuss Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol at AHA 2019.
Filmed on site at AHA 2019 by Radcliffe Cardiology.</p>
View more